PT  - JOURNAL ARTICLE
AU  - Atmar, Robert L.
AU  - Lyke, Kirsten E.
AU  - Deming, Meagan E.
AU  - Jackson, Lisa A.
AU  - Branche, Angela R.
AU  - El Sahly, Hana M.
AU  - Rostad, Christina A.
AU  - Martin, Judith M.
AU  - Johnston, Christine
AU  - Rupp, Richard E.
AU  - Mulligan, Mark J.
AU  - Brady, Rebecca C.
AU  - Frenck, Robert W.
AU  - Bäcker, Martín
AU  - Kottkamp, Angelica C.
AU  - Babu, Tara M.
AU  - Rajakumar, Kumaravel
AU  - Edupuganti, Srilatha
AU  - Dobryzynski, David
AU  - Posavad, Christine M.
AU  - Archer, Janet I.
AU  - Crandon, Sonja
AU  - Nayak, Seema U.
AU  - Szydlo, Daniel
AU  - Zemanek, Jillian
AU  - Islas, Clara P. Dominguez
AU  - Brown, Elizabeth R.
AU  - Suthar, Mehul S.
AU  - McElrath, M. Juliana
AU  - McDermott, Adrian B.
AU  - O’Connell, Sarah E.
AU  - Montefiori, David C.
AU  - Eaton, Amanda
AU  - Neuzil, Kathleen M.
AU  - Stephens, David S.
AU  - Roberts, Paul C.
AU  - Beigel, John H.
AU - the DMID 21-0012 Study Group
TI  - Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
AID  - 10.1101/2021.10.10.21264827
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.10.21264827
4099  - http://medrxiv.org/content/early/2021/10/15/2021.10.10.21264827.short
4100  - http://medrxiv.org/content/early/2021/10/15/2021.10.10.21264827.full
AB  - Background While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen.Methods In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×1010 virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29.Results 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 153 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations.Conclusion Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier.(Funded by National Institute of Allergy and Infectious Diseases; Clinical Trials.gov number, NCT04889209)Competing Interest StatementRLA, HME, RER, MB, TMB, ACK, DD, CMP, JLA, ABD, SEO, SC, SUN, DS, JZ, CPDI, ERB, MJM, and AE report no competing interests. KEL receives grant awards from the National Institute of Allergy and Infectious Disease (NIAID), and funding from Pfizer Inc COVID-19 vaccine research. LAJ's institution receives grant funding from NIH and CDC for vaccine-related assessments, including those of COVID-19 vaccines. ARB has grant funding from Pfizer, Janssen, Merck and Cyanvac for non-Covid-related work and servesa as a consultant for GSK and Janssen. CAR's institution has received funds to conduct clinical research from the National Institutes of Health, CDC, BioFire Inc, Genentech, GSK, Janssen, MedImmune, Merck, Micron, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology, which has been licensed to Meissa Vaccines, Inc. JMM has served as a consultant for Merck, Sharp and Dohme for non-Covid-related work. CJ receives funding from the Bill and Melinda Gates Foundation, NIH and CDC, consults for Gilead and Abbvie, serves on a DSMB for MedPace, and receives royalties from UpToDate. MJM has laboratory research and clinical trials contracts for vaccines or MAB vs SARS-CoV-2 with Lilly, Pfizer (exclusive of the current work), and Sanofi; personal fees for Scientific Advisory Board service from Merck, Meissa Vaccines, Inc. and Pfizer RCB receives funding for vaccine trials from Path Nipah and Pfizer. RWF receives funding to perform clinical trials from Pfizer, Moderna, Astra Zeneca and Emergent Health, and he serves on advisory boards for Johnson & Johnson, Merck, Sanofi Pasteur and Seqirus. SE receives funding to her institution from Sanofi Pasteur for a non-Dovid vaccine study. MSS is on the Advisory Board of Moderna DCM receives funding from NIH and Moderna for laboratory studies of COVID-19 vaccine antibody responses. KMN holds a grant from Pfizer, without salary support, for a COVID-19 vaccine study, and salary support from the National Institutes of Health (NIH) for work on multiple COVID-19 vaccine trials DSS is supported by grant awards from NIH/NIAID. PCR and JHB report a pending U.S. Patent Application No. 63/025,918 entitled Coronavirus RNA vaccines and methods of use Clinical TrialNCT04889209Funding StatementThe trial was sponsored and primarily funded by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), under award numbers UM1AI48372, UM1AI148373, UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148574, UM1AI148575, UM1AI148576, UM1AI148684, UM1 AI148689 and with support from the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00050 and NIH Vaccine Research Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra Center for IRB IntelligenceI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data produced in the present work are contained in the manuscript